135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC

Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG; Jänne P.; J?nne P.;Chih-Hsin Yang;Barrett C;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R

doi:10.1016/S1556-0864(16)30328-8

135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC

Journal

Journal of Thoracic Oncology

Journal Volume

11

Journal Issue

4

Date Issued

2016

Author(s)

Oxnard G.R

Thress K.S

Alden R.S

Lawrance R

Paweletz C.P

Cantarini M

Barrett C

CHIH-HSIN YANG

Jänne P.

DOI

10.1016/S1556-0864(16)30328-8

URI

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015248073&doi=10.1016%2fS1556-0864%2816%2930328-8&partnerID=40&md5=08576bb7b4e8cebb25cfeb3aeaf4f83a

https://scholars.lib.ntu.edu.tw/handle/123456789/494980

SDGs

[SDGs]SDG2

[SDGs]SDG3

Other Subjects

epidermal growth factor receptor; osimertinib; advanced cancer; Article; cohort analysis; controlled study; drug response; EGFR gene; false negative result; gene mutation; genotype; human; major clinical study; non small cell lung cancer; priority journal; progression free survival; treatment outcome

Publisher

Elsevier Inc

Type

journal article

135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC

關於 (About)

聯絡資訊 (Contact Us)

相關網站 (Useful Links)

關於開放取用 (Open Access, OA)

出版社期刊論文授權政策 (Copyright)

使用說明 (Instructions)

登入說明 (Sign-in)

匯入著作 (Submission)